Latest news with #GEHealthCareTechnologiesInc
Yahoo
17-05-2025
- Business
- Yahoo
Jim Cramer Says He is Not a 'Backer' of GE HealthCare Technologies (GEHC)
A caller asked if GE HealthCare Technologies Inc. (NASDAQ:GEHC) is worth another look, and in response, Cramer said: 'Okay, now you know, you're a club member, you know I sold a lot in the high 80s and then gave up on the rest. The reason I did was because it's inconsistent and too controlled by China, not America. So I am not going to be a backer. I am going to say the fabled [don't buy, don't buy, don't buy].' A radiologist in a lab examining a computed tomography scan of a patient. GE HealthCare (NASDAQ:GEHC) develops, manufactures, and markets a range of products, services, and digital tools that support the diagnosis, treatment, and monitoring of patients. The company reported a 3% year-over-year increase in revenue for the first quarter of 2025. The adjusted EBIT margin rose to 15.0% from 14.7%, and adjusted EPS increased to $1.01 from $0.90. Furthermore, free cash flow declined to $98 million, down from $274 million in the same quarter last year. While we acknowledge the potential of GEHC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GEHC and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: Jim Cramer Commented on These 6 Natural Gas Players and 13 Stocks on Jim Cramer's Radar Recently Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Jim Cramer Says He is Not a 'Backer' of GE HealthCare Technologies (GEHC)
A caller asked if GE HealthCare Technologies Inc. (NASDAQ:GEHC) is worth another look, and in response, Cramer said: 'Okay, now you know, you're a club member, you know I sold a lot in the high 80s and then gave up on the rest. The reason I did was because it's inconsistent and too controlled by China, not America. So I am not going to be a backer. I am going to say the fabled [don't buy, don't buy, don't buy].' A radiologist in a lab examining a computed tomography scan of a patient. GE HealthCare (NASDAQ:GEHC) develops, manufactures, and markets a range of products, services, and digital tools that support the diagnosis, treatment, and monitoring of patients. The company reported a 3% year-over-year increase in revenue for the first quarter of 2025. The adjusted EBIT margin rose to 15.0% from 14.7%, and adjusted EPS increased to $1.01 from $0.90. Furthermore, free cash flow declined to $98 million, down from $274 million in the same quarter last year. While we acknowledge the potential of GEHC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GEHC and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: Jim Cramer Commented on These 6 Natural Gas Players and 13 Stocks on Jim Cramer's Radar Recently Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
GE HealthCare Stock May Gain as FDA Approves Optison for Pediatric Use
GE HealthCare Technologies Inc. GEHC recently announced FDA approval for Optison, its polyethylene glycol (PEG)-free ultrasound enhancing agent, for use in pediatric patients. This milestone expands the application of Optison to children of all ages, enabling clearer and more accurate echocardiogram imaging. As one of the only ultrasound agents in the United States without PEG, Optison offers a safer alternative for patients with PEG hypersensitivity. With a proven safety profile and decades of clinical use in adults, this FDA approval follows successful studies demonstrating Optison's efficacy in pediatric heart imaging. GE HealthCare's expanded pediatric indication reflects its commitment to advancing diagnostic tools that improve accuracy while addressing patient safety and comfort, positioning Optison as a vital solution in pediatric cardiology diagnostics. Shares of the company closed flat at $72.84 yesterday following the announcement. In the year-to-date period, GEHC shares have lost 6.9% against the industry's 5.5% growth. The S&P 500 decreased 0.6% in the same time frame. The FDA approval of Optison for pediatric use significantly broadens GEHC's market potential by enabling access to a new and critical patient segment. This expansion not only reinforces GEHC's leadership in ultrasound imaging agents but also drives incremental revenue growth through increased adoption in pediatric cardiology. The product is positioned to capture greater market share amid rising demand for advanced, non-invasive diagnostic tools. Over the long term, this approval strengthens GEHC's competitive edge, supports sustained earnings growth, and enhances investor confidence, making the stock poised for upward momentum. Meanwhile, GEHC currently has a market capitalization of $33.81 billion. In the last reported quarter, GEHC delivered an earnings surprise of 10.9%. Image Source: Zacks Investment Research Optison is an advanced ultrasound enhancing agent developed by GEHC, designed to improve the clarity and diagnostic accuracy of echocardiograms. By using gas-filled microbubbles that reflect ultrasound waves more effectively than surrounding tissues or blood, Optison enhances the visibility of the heart chambers and endocardial borders. This improved imaging capability is crucial for cardiologists to assess ventricular function and diagnose heart abnormalities or diseases accurately. Importantly, Optison is the only ultrasound enhancing agent available in the United States that does not contain PEG, a substance known to cause hypersensitivity or anaphylaxis in some patients, making it a safer option for individuals with PEG allergies. The recent FDA approval for Optison's pediatric indication marks a significant milestone for GEHC. Previously approved for adult use since 1997, Optison's pediatric approval follows a comprehensive Phase IV clinical study that demonstrated its efficacy and safety in children aged 9 to 17. This approval allows cardiologists to extend the use of Optison to pediatric patients with suboptimal echocardiograms, addressing the challenge of obtaining clear heart images in younger patients. The clinical study demonstrated that Optison enhanced the delineation of endocardial borders, improved visualization of left ventricular wall segments, and reduced the number of suboptimal echocardiogram images, thereby facilitating more accurate diagnoses and informed treatment decisions for pediatric heart conditions. Beyond its diagnostic benefits, Optison's unique safety profile adds considerable value in clinical settings. Unlike many other contrast agents, Optison's PEG-free formulation reduces the risk of hypersensitivity reactions, which is particularly important for vulnerable pediatric patients. Despite its proven safety over decades and use in over 5 million adult patients in the United States, serious adverse reactions remain rare but are closely monitored, with guidelines emphasizing the importance of patient assessment and the availability of resuscitation equipment during administration. The FDA approval of Optison for pediatric use is set to significantly strengthen GE HealthCare's Pharmaceutical Diagnostics (PDx) segment by expanding its addressable market and driving increased adoption of its ultrasound-enhancing agents. By enabling use in pediatric patients, an important and previously underserved group, Optison can capture new revenue streams and deepen GEHC's footprint in cardiac imaging diagnostics. This approval also enhances the segment's product portfolio with a PEG-free contrast agent, differentiating it from competitors and meeting growing demand for safer, more effective diagnostic tools. Ultimately, this milestone supports PDx's growth trajectory by boosting clinical adoption, improving patient outcomes, and reinforcing GE HealthCare's leadership in innovative diagnostic solutions. GEHC carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and Boston Scientific Corporation BSX. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. CVS Health has a long-term estimated growth rate of 11.4%. CVS's earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 13.3%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
13-05-2025
- Business
- Yahoo
Is GE HealthCare Technologies (GEHC) the Best Young Stock to Buy According to Hedge Funds?
We recently published a list of the 11 Best Young Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where GE HealthCare Technologies Inc. (NASDAQ:GEHC) stands against other best young stocks. NASDAQ CEO and chair Adena Friedman appeared on CNBC's 'Squawk Box' on April 24 to discuss what to make of the market volatility, as well as the IPO landscape. Friedman reported that NASDAQ achieved 12.5% overall revenue growth in the quarter, with every division posting double-digit increases. Specifically, the index business grew by 26%, which was supported by $27 billion of inflows during the quarter. Half of these inflows were directed into NASDAQ 100 index products, while the other half went into various other indexes offered by NASDAQ. Friedman also acknowledged that the economy entered the year with resilience but faced increasing uncertainty and volatility as the quarter progressed. However, she explained that such environments often drive clients to turn to NASDAQ as the market operator of choice to manage their trading volumes and capital flows. She noted that even amid market value fluctuations, NASDAQ saw inflows into its index products and strong demand for its fintech services. The discussion also indicated that while short-term market volatility can boost trading activity and liquidity, longer-term IPO prospects depend on broader economic conditions. Friedman said that IPO activity and investor behavior could change more significantly if the economy were to enter an extended recession. But for now, NASDAQ benefits from a strong start to the year and remains a preferred venue for investors to express their views. The conversation then turned to global capital flows, particularly as Chinese sovereign wealth funds may reduce investments in US venture capital and private equity firms. Friedman stated that the capital flows where returns are the strongest. She emphasized that asset owners and managers have 'fiduciary' responsibilities to their ultimate beneficiaries and will prioritize returns over the long term. Acknowledging the influence of geopolitical and political factors on investment decisions, Friedman stressed that NASDAQ's role is to provide the infrastructure that allows capital to flow efficiently regardless of shifts. We first used the Finviz stock screener to compile a list of young stocks that went public in the last 3 years. We then selected the 11 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A radiologist in a lab examining a computed tomography scan of a patient. Number of Hedge Fund Holders: 64 GE HealthCare Technologies Inc. (NASDAQ:GEHC) develops, manufactures, and markets products, services, and complementary digital solutions. These are used in the diagnosis, treatment, and monitoring of patients in the US, Canada, and internationally. It has four segments: Imaging, Advanced Visualization Solutions/AVS, Patient Care Solutions/PCS, and Pharmaceutical Diagnostics/PDx. The Pharmaceutical Diagnostics segment generated 8% year-over-year organic revenue growth in Q1 2025 due to the introduction of new products. This growth was also driven by a focus on radiopharmaceuticals. In Q1 2025, GE Healthcare achieved the first commercial doses of Flyrcado, which is its novel PET myocardial perfusion imaging agent designed to detect coronary artery disease. This tracer has also received CMS pass-through pricing, paving the way for a successful rollout. The company also strengthened its position by acquiring the remaining 50% stake in Nihon Medi-Physics/NMP in Q1. NMP is a radiopharmaceutical company in Japan that is expected to contribute ~$150 million of inorganic revenue over the remaining three quarters of 2025. Patrick Wood from Morgan Stanley maintained a Hold rating on GE Healthcare with a price target of $78 on May 7. Oakmark Fund stated the following regarding GE HealthCare Technologies Inc. (NASDAQ:GEHC) in its Q4 2024 investor letter: 'GE HealthCare Technologies Inc. (NASDAQ:GEHC) is a leading global medical technology company that was spun off from General Electric in January 2023. As a standalone company, we expect GE HealthCare to benefit from increased focus, better aligned management and incentives, and an improved corporate culture. We believe these changes will help drive higher margins and organic growth. In addition, we think GE HealthCare is well-positioned to capitalize on technology trends as a greater portion of the value proposition comes from AI-enabled software and a shift toward precision care. A lack of appreciation for the company's self-help potential coupled with short-term concerns around weak demand in China provided us with the opportunity to purchase shares at a low valuation relative to other high-quality medical technology companies and at the lowest price relative to the S&P 500 since the IPO.' Overall, GEHC ranks 5th on our list of the best young stocks to buy according to hedge funds. While we acknowledge the growth potential of GEHC, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than GEHC but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
GEHC Stock Surges as SIGNA Sprint MRI Redefines 1.5T Imaging Tech
GE HealthCare Technologies Inc. GEHC recently introduced SIGNA Sprint, a next-generation ultra-premium 1.5T MRI system at the International Society for Magnetic Resonance in Medicine (ISMRM) 2025, engineered to push the boundaries of traditional MRI performance. With a 65/200 per-axis gradient strength and built-in AI tools, SIGNA Sprint delivers sharp imaging for cardiology and oncology, enabling faster, more accurate diagnostics. As healthcare providers increasingly prioritize imaging solutions that balance diagnostic power, cost-effectiveness and patient comfort, SIGNA Sprint stands out with its blend of cutting-edge performance and accessibility. Built-in AI technologies streamline workflows while its patient-centric design, including free-breathing capability and AIR Coils, enhances the overall imaging experience. With SIGNA Sprint, GE HealthCare aims to redefine what's possible at 1.5T, expanding clinical capabilities without the added infrastructure demands of higher-field MRI systems. Shares of the company moved north 6.1% and closed at $74.11 on Monday following the announcement, primarily due to the U.S.-China trade deal. In the year-to-date period, GEHC shares have lost 5.3% against the industry's 5.3% growth. The S&P 500 decreased 4.5% in the same time frame. The launch of SIGNA Sprint positions GE HealthCare to strengthen its premium MRI market presence with a cost-effective, high-performance alternative to 3.0T systems. Its AI-driven capabilities and enhanced diagnostic features make it appealing to hospitals and research institutions, driving adoption and recurring service revenue. This innovation could support sustained revenue growth, improve investor confidence, and enhance long-term stock performance. Meanwhile, GEHC currently has a market capitalization of $31.99 billion. In the last reported quarter, GEHC delivered an earnings surprise of 10.9%. Image Source: Zacks Investment Research SIGNA Sprint is an ultra-premium, wide-bore MRI system designed to deliver imaging power typically found in 3.0T systems on the more accessible 1.5T platform. A FDA 510(k) application is pending for the system, and clearance is expected to expand GEHC's diagnostic capabilities in cardiology, oncology, and other advanced clinical and research domains. It delivers exceptional diffusion imaging, vital for oncology, and enables crystal-clear visualization of sub-millimetric structures critical in precision care. SIGNA Sprint's core advantage lies in its integrated AI technologies, AIR Recon DL, Sonic DL, and AIR x, which enhance image reconstruction, accelerate scan times, and improve diagnostic accuracy. These deep learning tools enable quantitative MRI, offering deeper insights into tissue characteristics, particularly in cardiac imaging, while streamlining workflows and enhancing treatment monitoring. Designed for patient comfort with a 70cm wide bore, free-breathing capabilities, and AIR Coils, SIGNA Sprint combines advanced imaging power with improved patient experience. As demand for scalable MRI solutions rises, particularly in cardiology and oncology, SIGNA Sprint offers a cost-effective, AI-powered system poised to drive both clinical impact and commercial success for GE HealthCare. At ISMRM 2025, GE HealthCare is expected to showcase its latest MRI innovations, including SIGNA Sprint, which features SIGNA MAGNUS— a high-resolution head-only scanner with advanced gradients. Additionally, Sonic DL 3D, a deep learning-based MRI acceleration technology, and Freelium, a helium-free sealed magnet platform in development to reduce helium reliance, are also expected to be showcased. These advancements highlight GE HealthCare's leadership in MRI technology. In recent months, GEHC has made strategic moves to expand its imaging services and AI capabilities. In March, GEHC unveiled Freelium, a next-generation sealed magnet platform at ECR 2025, designed to revolutionize Magnetic Resonance imaging. The platform uses less than 1% of helium compared to traditional systems, promoting sustainability and expanding access to quality imaging in helium-scarce regions. In January, GEHC partnered with Sutter Health to form a seven-year Care Alliance, enhancing access to innovative imaging services and improving the patient and clinician experience across the Sutter Health network. This collaboration aims to create a more seamless and coordinated healthcare system. GEHC carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and Boston Scientific Corporation BSX. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. CVS Health has a long-term estimated growth rate of 11.4%. CVS's earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 13.3%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
